Immuno-Oncology | Specialty

Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC

August 5th 2016

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016

Nivolumab Misses PFS Endpoint in Frontline Phase III NSCLC Study

August 5th 2016

Monotherapy with nivolumab failed to improve progression-free survival compared with physician's choice of combination chemotherapy for patients with PD-L1–positive non–small cell lung cancer.

Dr. Garon on Immunotherapy for Patients With NSCLC

August 5th 2016

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.

New Immunotherapy Classes Emerge in Lung Cancer

August 4th 2016

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

New Checkpoint Target Emerges in Bladder Cancer

August 4th 2016

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Pembrolizumab Gains European Approval for PD-L1+ NSCLC

August 3rd 2016

The European Commission has approved pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer following at least 1 chemotherapy regimen.

Dr. Peter O'Donnell on Atezolizumab and IMvigor 210

August 2nd 2016

Testing the Immune Memory: How Much Anti-PD-1/PD-L1 Therapy Is Enough?

August 2nd 2016

There is some evidence that relatively short treatment courses might also be appropriate for other checkpoint inhibitors approved for treating some cancers, but the data are fairly sparse.

Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology

August 1st 2016

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses how the use of PD-1/PD-L1 inhibitors in multiple tumor types has dramatically evolved over the last 4 years.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016

Novel Agents with Len-Dex in Multiple Myeloma

July 27th 2016

Goals of Therapy for Relapsed Myeloma

July 27th 2016

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016

All Myeloma Relapses Are Not the Same

July 27th 2016

Efficacy and Safety of Monoclonal Antibodies for Multiple Myeloma

July 27th 2016